Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04532554
  4. Details
NCT04532554 Clinical Trial

Growth Hormone in Obese Cases With Covid-19

Covid19 Clinical Trial

Official title:
The Impact of Growth Hormone in Obese Cases With Covid-19

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT04532554
Other study ID # PR0015
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date October 26, 2020
Est. completion date December 20, 2020

Study information
Verified date September 2020
Source ClinAmygate
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Description:

It is well known that lymphoid organs such the thymus, the spleen and peripheral blood produce growth hormone (GH) and GH receptor is expressed on different subpopulations of lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis, enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine response.

The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date December 20, 2020
Est. primary completion date December 10, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Obese with BMI > 30

Exclusion Criteria:

- History of hypersensitivity to GH

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Growth Hormone
Recombinant growth hormone will be used
• Placebo
Saline injection with the same amount

Locations
Country Name City State
Egypt Asalam Maadi Cairo

Sponsors (1)
Lead Sponsor Collaborator
ClinAmygate

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev. 2004 Aug;1 Suppl 3:490-5. Review. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary Need for hospitalization need to be hospitalized due to deterioration one to two weeks
Secondary Time to recovery Time to recovery from symptoms and signs one to four weeks
Secondary Percentage of reduction in CRP Percentage of reduction in CRP one to two weeks
Secondary Percentage of reduction in LDH Percentage of reduction in LDH one to two weeks
Secondary Percentage of reduction in Ferritin Percentage of reduction in Ferritin one to two weeks
Secondary Time to recovery from leucopenia Time to recovery from leucopenia one to two weeks
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3

External Links